Header Logo

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to Jensen, Donald
Item TypeName
Concept Hepatitis C, Chronic
Concept Hepatitis B, Chronic
Academic Article Sticker shock and the price of new therapies for hepatitis C: is it worth it?
Academic Article Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C.
Academic Article Rationale and design of the REPEAT study: a phase III, randomized, clinical trial of peginterferon alfa-2a (40 kDa) plus ribavirin in non-responders to peginterferon alfa-2b (12 kDa) plus ribavirin.
Academic Article Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy.
Academic Article Retreatment of chronic hepatitis C in previous non-responders and relapsers.
Academic Article Future directions in therapy for chronic hepatitis C.
Academic Article Ribavirin in the treatment of chronic hepatitis C.
Academic Article Hepatitis C: current and future therapies.
Academic Article Marked flare in hepatic aminotransferases during treatment with pegylated interferon for chronic hepatitis C, genotype 2: a case report.
Academic Article Sustained viral response after interferon-based therapy in chronic hepatitis C: more evidence to support a life-long cure.
Academic Article Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial.
Academic Article A new era of hepatitis C therapy begins.
Academic Article Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future.
Academic Article Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients.
Academic Article IL28B genetic polymorphism testing in the era of direct acting antivirals therapy for chronic hepatitis C: ten years too late?
Academic Article Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies.
Academic Article Future therapies for chronic hepatitis C.
Academic Article Predicting early and sustained virological responses in prior nonresponders to pegylated interferon alpha-2b plus ribavirin retreated with peginterferon alpha-2a plus ribavirin and the benefit-risk ratio of retreatment.
Academic Article The FDA, bridging data, and hepatitis C.
Academic Article Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
Academic Article Human immunodeficiency virus and coinfection with hepatitis B and C.
Academic Article Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin.
Academic Article Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C.
Academic Article Interferon-free regimens containing setrobuvir for patients with genotype 1 chronic hepatitis C: a randomized, multicenter study.
Academic Article Retinoid and carotenoid status in serum and liver among patients at high-risk for liver cancer.
Academic Article Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis.
Academic Article Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy.
Search Criteria
  • Hepatitis B Chronic